background
sever
acut
respiratori
syndrom
sar
emerg
infect
caus
novel
coronaviru
known
sarscov
character
overexuber
immun
respons
lung
lymphomononuclear
cell
infiltr
prolifer
may
account
tissu
damag
direct
effect
viral
replic
studi
aim
investig
capabl
sarscov
activ
ifna
g
express
lymphomonocyt
pbmc
healthi
donor
evalu
whether
viral
replic
necessari
activ
result
sarscov
viru
abl
induc
ifna
g
mrna
accumul
protein
releas
dosedepend
manner
moi
effect
time
cours
curv
indic
ifna
mrna
induct
peak
hpi
wherea
ifng
mrna
still
increas
hpi
releas
ifn
type
reach
plateau
hpi
remain
rather
stabl
period
transient
peak
neg
strand
viral
rna
detect
day
infect
neither
infecti
viru
progeni
yield
newli
produc
viral
genom
rna
could
evidenc
infect
cultur
even
prolong
observ
time
day
cocultiv
pbmc
fix
sarscovinfect
vero
cell
even
effici
exposur
live
viru
elicit
ifna
g
induct
combin
ifna
g
strongli
inhibit
sarscov
replic
vero
cell
singl
cytokin
much
less
effect
conclus
studi
provid
evid
sarscov
abl
induc
normal
pbmc
coordin
induct
ifna
g
gene
express
viru
replic
necessari
ifn
induct
sinc
effici
ifn
express
could
obtain
also
cocultiv
normal
pbmc
fix
sarscovinfect
cell
concomit
activ
ifna
g
gene
express
sarscov
vivo
may
relev
pathogenesi
diseas
possibl
involv
immunomedi
damag
tissu
strong
inhibit
sarscov
replic
result
combin
cytokin
action
sever
acut
respiratori
syndrom
sar
emerg
infect
caus
novel
coronaviru
known
sarscov
drosten
et
al
ill
character
inflammatori
exud
alveoli
interstiti
tissu
accompani
hyperplasia
fibrou
tissu
fibrosi
nichol
et
al
destruct
lung
tissu
thought
result
overexuber
immun
respons
rather
direct
effect
viral
replic
particularli
shown
ifng
may
activ
sar
patient
wong
et
al
cameron
mj
intern
confer
sar
lubeck
may
suggest
proinflammatori
cytokin
may
associ
lung
infiltr
prolifer
lymphomononuclear
cell
nichol
et
al
wong
et
al
bauer
et
al
beij
group
nation
research
project
sar
anoth
clinic
featur
sar
leukopenia
wong
et
al
may
consequ
recruit
lymphomonocyt
peripheri
inflam
tissu
short
time
onset
diseas
presenc
replic
intermedi
sarscov
shown
peripher
blood
mononuclear
cell
pbmc
taken
patient
li
et
al
addit
sarscov
genom
replic
detect
pbmc
vitro
ng
et
al
low
titer
infecti
progeni
product
observ
cultur
purifi
monocytemacrophag
yilla
et
al
minut
variabl
amount
ifna
detect
cultur
suggest
potenti
role
cytokin
restrict
sarscov
replic
monocyt
vitro
recent
macrophag
mf
monocytederiv
dendrit
cell
dc
shown
unabl
sustain
product
replic
sarscov
although
initi
phase
viru
replic
cycl
detect
latter
cell
tseng
et
al
law
et
al
studi
aim
investig
capabl
sarscov
activ
ifna
g
product
pbmc
healthi
donor
establish
whether
product
infect
essenti
activ
ifn
respons
first
issu
normal
pbmc
expos
infecti
sarscov
variou
multipl
infect
moi
viru
replic
activ
ifna
g
gene
express
determin
second
issu
normal
pbmc
cocultiv
fix
sarscovinfect
cell
activ
ifn
respons
determin
well
test
abil
sarscov
induc
ifn
normal
pbmc
dosedepend
experi
perform
expos
purifi
blood
cell
viru
moi
rang
level
ifna
g
mrna
cell
correspond
cytokin
level
supernat
measur
result
repres
experi
shown
fig
indic
sarscov
abl
induc
ifna
g
mrna
dosedepend
manner
moi
effect
fig
addit
ifna
mrna
level
reach
peak
h
wherea
ifng
mrna
level
steadili
increas
h
cultur
fig
dosedepend
kinet
ifna
g
releas
supernat
shown
fig
consist
mrna
result
releas
ifn
type
reach
plateau
hpi
fig
remain
rather
stabl
day
pi
start
declin
thereaft
shown
respons
sarscov
infect
consist
found
pbmc
differ
donor
although
great
variat
extent
respons
give
idea
variat
individu
result
differ
donor
refer
one
repres
time
dose
shown
fig
g
mrna
fig
h
immunoreact
cytokin
stimul
ifn
respons
sarscov
observ
experi
seen
extent
respons
mrna
vari
stimul
background
even
pronounc
measur
cytokin
level
elisa
overal
pattern
variat
concord
mrna
elisa
individu
pbmc
level
suggest
mere
reflect
differ
activ
state
pbmc
differ
donor
abil
sarscov
product
infect
normal
pbmc
determin
cultur
use
ifn
induct
experi
extend
observ
period
day
period
sampl
cultur
measur
sever
paramet
indic
viru
replic
fig
infecti
viru
concentr
pbmc
infect
variou
moi
shown
decreas
amount
infecti
viru
observ
along
whole
studi
period
probabl
result
thermal
inactiv
residu
viral
inoculum
suggest
absenc
newli
form
progeni
yield
similar
result
also
obtain
mitogen
phytohemoagglutinin
pha
activ
pbmc
shown
test
least
part
viru
replic
cycl
took
place
pbmc
measur
level
virusspecif
minusrna
strand
genom
rna
peak
minusrna
strand
could
visual
low
moi
due
high
background
inoculum
higher
moi
wherea
genom
rna
quantif
reveal
trend
similar
infecti
viru
yield
titrat
decreas
residu
inoculum
detect
along
whole
observ
period
shown
lower
background
nois
high
moi
repeat
infect
experi
pbmc
addit
donor
perform
trypsin
extens
wash
cell
adsorbt
phase
condit
could
clearli
appreci
peak
minu
strand
viral
rna
pbmc
sampl
rang
increas
background
level
two
pbmc
sampl
peak
observ
day
pi
one
pbmc
sampl
observ
day
pi
follow
declin
background
level
thereaft
case
fig
show
one
repres
case
howev
also
condit
increas
either
infect
genom
rna
could
appreci
shown
fig
c
damag
pbmc
appar
occur
cultur
assess
overal
mortal
apoptot
cell
death
never
exceed
background
level
result
suggest
occurr
incomplet
viru
replic
cycl
pbmc
verifi
occurr
complet
even
partial
replic
cycl
sarscov
requir
ifn
induct
pbmc
whether
ifn
induct
could
trigger
also
absenc
viru
replic
use
fix
sarscovinfect
vero
cell
ifn
induc
aim
normal
pbmc
cocultiv
fix
sarscovinfect
vero
cell
differ
ratio
fix
uninfect
vero
cell
use
neg
control
fig
show
result
repres
doseand
timedepend
experi
seen
ifn
type
dosedepend
induc
fix
sarscovinfect
cell
furthermor
ifna
releas
peak
day
remain
plateau
level
thereaft
wherea
ifng
reach
plateau
level
hpi
highest
concentr
induc
still
increas
time
lower
induc
concentr
similar
result
obtain
pbmc
differ
donor
although
variabl
extent
respons
fact
rang
peak
ifna
g
level
respect
shown
whole
ifn
respons
higher
observ
experi
use
live
viru
sinc
averag
cytokin
level
higher
ifna
g
respect
classic
viru
yield
experi
vero
cell
treat
either
ifna
alon
iuml
ifng
alon
iuml
combin
infect
sarscov
moi
result
three
experi
shown
fig
indic
mean
reduct
viru
yield
day
pi
log
ifna
ifng
respect
p
pbmc
infect
sarscov
differ
moi
overnight
incub
mrna
level
specif
ifna
r
g
measur
limit
dilut
rtpcr
express
ratio
hactin
mrna
describ
method
section
releas
cytokin
detect
elisa
b
express
pgml
c
repres
time
cours
experi
pbmc
expos
indic
time
sarscov
moi
level
mrna
ifna
r
g
releas
cytokin
determin
panel
b
respect
e
g
peak
level
mrna
ifna
hpi
ifng
hpi
pbmc
differ
donor
infect
sarscov
moi
result
express
ratio
level
unstimul
cultur
f
h
level
releas
ifna
hpi
ifng
hpi
pbmc
cultur
shown
panel
e
g
result
express
pgml
much
stronger
reduct
log
combin
ifn
type
use
p
coordin
induct
ifna
g
unprim
pbmc
cultur
vitro
wellestablish
phenomenon
common
differ
virus
influenza
parainfluenza
virus
well
capobianchi
et
al
studi
extend
observ
recent
discov
etiolog
agent
sar
obtain
evid
sarscov
intrins
abil
activ
ifna
g
gene
express
pbmc
cultur
fact
observ
doseand
timedepend
induct
mrna
protein
releas
cytokin
use
live
viru
ifn
induc
normal
pbmc
cultur
recent
sarscov
antigen
shown
abl
induc
recal
respons
includ
product
ifng
pbmc
vaccin
mice
takasuka
et
al
knowledg
previou
data
show
ifng
respons
sarscov
unprim
human
pbmc
kinet
induct
ifna
g
mrna
observ
sarscovexpos
pbmc
cultur
line
expect
kinet
induct
virus
point
supernat
collect
immunoreact
ifna
g
b
detect
elisa
ifna
g
level
supernat
cocultur
pbmc
uninfect
fix
vero
cell
lower
detect
limit
pgml
ifna
pgml
ifng
respect
shown
cell
extens
wash
fresh
medium
ad
time
sampl
cultur
perform
indic
time
point
day
one
repres
experi
shown
result
express
tcid
ml
b
c
infect
b
viral
rna
posit
neg
strand
c
pbmc
infect
moi
treat
trypsin
adsorbt
phase
one
repres
experi
shown
infect
express
tcid
ml
viral
genom
rna
log
copi
pbmc
neg
strand
viral
rna
log
ratio
hactin
fig
reduct
infecti
viru
yield
vero
cell
ifna
g
use
singularli
combin
vero
cell
treat
either
ifna
alon
iuml
ifng
alon
iuml
combin
infect
sarscov
moi
day
progeni
viru
harvest
titrat
result
express
mean
viru
yield
log
tcid
experi
bar
indic
standard
error
mean
statist
evalu
reduct
versu
control
cultur
ifna
p
ifng
p
ifna
ifng
p
capobianchi
et
al
transient
ifna
mrna
activ
howev
level
cytokin
supernat
show
similar
pattern
ifn
type
stabl
day
respons
sarscov
infect
consist
found
pbmc
differ
donor
although
extent
respons
vari
among
individu
also
observ
sarscovinfect
monocyt
yilla
et
al
studi
also
obtain
evid
product
infect
pbmc
mandatori
ifn
induct
two
line
evid
peak
sarscov
infecti
progeni
detect
pbmc
cultur
effici
ifn
induct
could
achiev
pbmc
cocultiv
fix
sarscovinfect
cell
concern
first
line
evid
present
studi
add
signific
advanc
previou
data
fact
recent
result
anoth
group
indic
sarscov
abl
infect
vitro
pbmc
determin
virusspecif
rna
product
ng
et
al
howev
infecti
viral
yield
test
paper
show
experiment
condit
product
viral
replic
occur
pbmc
although
initi
phase
viru
infect
take
place
fact
viral
infect
genom
rna
progress
decreas
along
observ
time
even
remov
background
level
trypsin
fail
detect
increas
infecti
progeni
yield
genom
rna
howev
remov
background
nois
allow
us
consist
detect
peak
newli
form
neg
strand
day
pi
declin
thereaft
find
suggest
condit
initi
phase
viru
replic
start
pbmc
cycl
progress
complet
damag
pbmc
appar
occur
cultur
assess
overal
mortal
apoptot
cell
death
support
absenc
viru
replic
bulk
pbmc
cultur
result
remind
observ
two
recent
studi
blood
mononuclear
cell
cultur
tseng
et
al
law
et
al
particularli
studi
tseng
et
al
infecti
viru
titer
progress
decreas
viral
subgenom
rna
produc
primari
mf
monocytederiv
dc
author
conclud
cell
sarscov
fail
establish
product
infect
although
affect
function
cell
type
tseng
et
al
similarli
law
et
al
observ
product
infecti
viru
yield
dc
although
initi
phase
viral
replic
seem
occur
law
et
al
concern
second
line
evid
fact
effici
induct
ifna
g
could
achiev
pbmc
also
cocultiv
fix
sarscovinfect
cell
may
suggest
involv
ifn
induct
membran
mechan
lead
activ
intern
pathway
ifn
gene
express
previous
shown
virus
includ
hiv
hsv
anim
coronavirus
capobianchi
et
al
capobianchi
et
al
charley
laud
glycoprotein
expos
infect
cell
could
involv
ifn
induct
although
mechan
need
still
elucid
gener
believ
ifn
system
play
pivot
role
host
defens
virus
reason
assum
lymphomonocyt
expos
high
concentr
sarscov
bodi
site
viru
replic
take
place
ifn
activ
occur
result
either
direct
although
non
product
pbmc
infect
exposur
infect
cell
bystand
effect
therefor
ifna
g
product
pbmc
expos
sarscov
expect
occur
vivo
particip
inflammatori
event
take
place
diseas
tissu
concomit
activ
ifna
g
gene
express
shown
first
time
relev
pathogenesi
diseas
fact
sarscov
shown
poorli
sensit
antivir
action
ifna
g
use
singularli
strongli
inhibit
combin
two
cytokin
stroher
et
al
hensley
et
al
antonelli
et
al
present
result
observ
mani
virus
therefor
natur
respons
sarscov
exert
lymphomononuclear
cell
lead
concomit
activ
type
ii
ifn
respons
result
strong
inhibit
sarscov
replic
light
result
possibl
ad
valu
therapeut
intervent
combin
ifn
administr
diseas
patient
taken
consider
although
data
necessari
clarifi
role
endogen
activ
ifn
system
sar
vero
cell
maintain
modifi
eagl
medium
mem
supplement
fetal
calf
serum
fc
c
humidifi
atmospher
viru
stock
prepar
vero
cell
infect
sarscov
isol
provid
h
feldmann
dept
medic
microbiolog
manitoba
canada
moi
tcid
cell
viru
harvest
cell
monolay
show
cytopath
effect
freez
thaw
three
time
cell
lysat
clarifi
aliquot
store
c
viru
titrat
perform
vero
cell
limit
dilut
assay
result
express
tcid
ml
sensit
log
tcid
ml
viru
stock
titer
tcid
ml
prepar
fix
cell
vero
cell
infect
mock
viru
prepar
sarscov
moi
tcid
cell
seven
hour
postinfect
cell
monolay
wash
twice
pb
detach
mm
edta
extens
wash
expos
paraformaldehyd
pb
min
c
cell
extens
wash
resuspend
cellsml
rpmi
contain
fc
kept
ice
use
pbmc
obtain
healthi
donor
ficol
hypaqu
pharmacia
sweden
densiti
centrifug
cultur
perform
rpmi
medium
gibco
usa
contain
fc
antibiot
pbmc
donor
use
infect
experi
peripher
blood
mononuclear
cell
infect
min
c
differ
moi
rang
wash
reseed
ml
rpmi
fc
incub
c
experi
pbmc
expos
trypsin
mg
ml
min
remov
viru
inoculum
wash
time
reseed
day
half
amount
medium
replac
fresh
complet
medium
indic
time
total
cellular
rna
extract
trizol
life
technolog
ny
usa
accord
manufactur
protocol
parallel
whole
clarifi
cultur
lysat
obtain
three
cycl
freez
thaw
assay
viru
titrat
vero
cell
accord
method
reed
muench
result
express
tcid
ml
experi
pbmc
unstimul
activ
agml
phytohemoagglutinin
pha
gibco
usa
use
cell
mortal
apoptosi
hypodiploid
cell
detect
day
pi
trypan
blue
propidium
iodid
stain
respect
order
detect
virusspecif
minusrna
strand
total
rna
extract
sarscovinfect
pbmc
retrotranscrib
presenc
sens
primer
nm
rt
buffer
invitrogen
mm
dntp
mm
dtt
u
mmlv
rt
invitrogen
min
c
denatur
target
c
min
amplif
carri
u
amplitaq
gold
appli
biosystem
pcr
buffer
appli
biosystem
mm
mgcl
mm
dntp
sens
antisens
primer
bniouta
nm
describ
drosten
et
al
amplifi
product
bp
detect
agaros
gel
electrophoresi
visual
uv
fluoresc
stain
ethidium
bromid
semiquantit
evalu
obtain
limit
dilut
rtpcr
normal
housekeep
gene
express
perform
run
parallel
amplif
hactin
mrna
measur
sarscov
genom
rna
perform
quantit
real
time
rtpcr
use
commerci
kit
realart
tm
hpacoronaviru
lc
rtpcr
artu
hamburg
germani
lightcycl
instrument
roch
diagnost
basel
switzerland
induct
experi
perform
freshli
collect
pbmc
ifn
induct
pbmc
perform
infect
live
sarscov
cocultiv
fix
sarscovinfect
vero
cell
first
issu
cell
ml
pbmc
infect
sarscov
viru
moi
rang
sampl
variou
time
point
pbmc
donor
use
set
experi
ifn
induct
fix
cell
freshli
isol
pbmc
cellsml
cultiv
presenc
vero
cell
either
uninfect
infect
sarscov
fix
paraformaldehyd
describ
differ
ratio
pbmc
donor
use
set
experi
posit
control
ifn
induct
newcastl
diseas
viru
ndv
use
experi
hemagglutin
unit
hu
cell
case
strong
respons
observ
ndvexpos
pbmc
indic
good
induc
ifna
g
experiment
condit
shown
total
rna
extract
trizol
retrotranscrib
random
exam
extens
method
determin
mrna
level
ifna
g
perform
limit
dilut
rtpcr
previous
describ
abbat
et
al
amplifi
product
analyz
agaros
gel
electrophoresi
result
express
ratio
hactin
releas
ifna
g
detect
enzymelink
immunosorb
assay
elisa
name
human
interferon
alpha
huifna
multisubtyp
elisa
kit
pbl
biomed
laboratori
measur
isotyp
huifna
elisa
ifng
purchas
pierc
biotechnolog
rockford
il
elisa
assay
cultur
supernat
pbmc
expos
live
viru
treat
triton
inactiv
residu
viral
infect
result
express
ifn
pgml
give
idea
interdonor
extent
variat
individu
result
pbmc
differ
donor
refer
peak
stimul
shown
result
section
express
ratio
control
mrna
pgml
immunoreact
protein
mean
reduct
viru
yield
singl
combin
ifn
treatment
evalu
student
test
cc
carri
ifn
induct
experi
draft
manuscript
lb
carri
ifn
induct
experi
el
ca
gr
perform
molecular
analysi
immunoassay
ia
fp
mrc
particip
studi
design
help
draft
manuscript
author
read
approv
final
manuscript
